Ben Carter | Chief Technology Officer
CytoSeek

Ben Carter, Chief Technology Officer, CytoSeek

Dr Carter completed his PhD in Cellular and Molecular Medicine at the University of Bristol. He studied artificial membrane-binding protein technology for use with enzymes, and is a co-inventor of the core technology now exploited by CytoSeek.

Appearances:



On-Floor Seminar: Thursday 16th May @ 11:20

Artificial membrane-binding proteins for cell therapies

  • The biodistribution of therapeutic cells
  • Artificial membrane-binding protein (AMBP) technology
  • Augmentation of therapeutic cells by AMBPs
last published: 25/Mar/19 17:15 GMT

back to speakers

There are two parts to the World Advanced Therapies & Regenerative Medicine Congress: a conference and an exhibition featuring solutions for pharma and biotech.

There is a registration fee to attend the conferences. To visit the exhibition is free.

TO SPONSOR / EXHIBIT

Erica Baeta 
+44 (0)207 092 1152 
erica.baeta@terrapinn.com

TO SPEAK

Jessica Robinson 
t/ +44 (0)207 092 1150 
jessica.robinson@terrapinn.com

TO REGISTER

Issa Mauthoor 
+44 (0)207 092 1257 
issa.mauthoor@terrapinn.com